<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000062856" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia.</SummaryDescription><SummaryURL xref="http://cancer.gov/types/leukemia/hp/cll-treatment-pdq">Chronic Lymphocytic Leukemia (PDQ®): Treatment</SummaryURL><MainTopics><TermRef ref="CDR0000037765">chronic lymphocytic leukemia</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Chronic Lymphocytic Leukemia Treatment  (PDQ®)</SummaryTitle><AltTitle TitleType="Navlabel">CLL Treatment</AltTitle><AltTitle TitleType="Short">Chronic Lymphocytic Leukemia Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000037765">chronic lymphocytic leukemia</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Chronic Lymphocytic Leukemia (CLL)</Title><SummarySection id="_235"><Title>Incidence and Mortality</Title><Para id="_236">Estimated new cases and deaths from CLL  in the United States in 2015:<Reference refidx="1"/></Para><ItemizedList id="_237" Style="bullet"><ListItem>New cases:  14,620.</ListItem><ListItem>Deaths:  4,650.</ListItem></ItemizedList></SummarySection><Para id="_3"> CLL is a disorder of morphologically mature but
immunologically less mature lymphocytes and is manifested by progressive
accumulation of these cells in the blood, bone marrow, and lymphatic tissues.<Reference refidx="2"/> 
In this disorder, lymphocyte counts in the blood are usually greater than or equal to 5,000/mm<Superscript>3</Superscript>  with a characteristic immunophenotype (CD5-  and CD23-positive B cells).<Reference refidx="3"/><Reference refidx="4"/>
  As assays have become more sensitive for detecting monoclonal B-CLL–like cells in peripheral blood, researchers have detected a monoclonal B-cell lymphocytosis (MBL) in 3% of adults older than 40 years and 6% in adults older than 60 years.<Reference refidx="5"/>  Such early detection and  diagnosis may falsely suggest improved survival for the group and may unnecessarily worry or result in therapy for some patients who would have remained undiagnosed in their lifetime, a circumstance known in the literature as overdiagnosis or pseudodisease.<Reference refidx="6"/><Reference refidx="7"/>  </Para><Para id="_309">In two selected series of more than  900 patients followed prospectively for a median of 5 to 7 years, overt CLL requiring chemotherapy occurred in 7% of patients.<Reference refidx="5"/><Reference refidx="8"/> In a database analysis and for  up to 77 months before diagnosis, almost all patients with a diagnosis of CLL had prediagnostic B-cell clones that were identified in peripheral blood when available.<Reference refidx="4"/><Reference refidx="9"/></Para><Para id="_124">For patients with progressing CLL, treatment with conventional doses of chemotherapy is not
curative; selected patients treated with allogeneic stem cell transplantation
have achieved prolonged disease-free survival.<Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/>  Antileukemic
therapy is frequently unnecessary in uncomplicated early disease.<Reference refidx="15"/> The median survival for all patients ranges from 8 to 12 years in older trials with data from the 1970s through the 1990s.<Reference refidx="15"/><Reference refidx="16"/> There is, however, a large variation in survival among individual patients, ranging from several months to a normal life expectancy.  Treatment must be individualized based on the clinical behavior of the disease.<Reference refidx="17"/></Para><Para id="_4">As found in one  report,  CLL occurs primarily in middle-aged and elderly adults, with increasing
frequency in successive decades of life.<Reference refidx="18"/>  The clinical course of this
disease progresses from an indolent lymphocytosis without other evident disease
to one of generalized lymphatic enlargement with concomitant pancytopenia. 
Complications of pancytopenia, including hemorrhage and infection, represent a
major cause of death in these patients.<Reference refidx="19"/>  Immunological aberrations,
including Coombs-positive hemolytic anemia, immune thrombocytopenia, and
depressed immunoglobulin levels may all complicate the management of CLL.<Reference refidx="20"/> 
Prognostic factors that may help predict clinical outcome include cytogenetic
subgroup,  immunoglobulin mutational status, ZAP-70, and CD38.<Reference refidx="2"/><Reference refidx="21"/><Reference refidx="22"/><Reference refidx="23"/><Reference refidx="24"/><Reference refidx="25"/><Reference refidx="26"/><Reference refidx="27"/><Reference refidx="28"/><Reference refidx="29"/> (Refer to the  <SummaryRef href="CDR0000062856#_179" url="/types/leukemia/hp/cll-treatment-pdq">Prognostic Factors</SummaryRef> section in the <SummaryRef href="CDR0000062856#_7" url="/types/leukemia/hp/cll-treatment-pdq">Stage Information for Chronic Lymphocytic Leukemia</SummaryRef> section of this summary for more information.) Patients who develop an aggressive high-grade non-Hodgkin lymphoma, usually diffuse large B-cell lymphoma and termed a Richter transformation, have a poor prognosis.<Reference refidx="30"/>
Patients with CLL are also at increased risk for other malignancies, even before therapy.<Reference refidx="31"/></Para><Para id="_5">Confusion with other diseases may be avoided by determination of cell surface
markers.  CLL lymphocytes coexpress the B-cell antigens CD19 and CD20 along
with the T-cell antigen CD5.<Reference refidx="32"/>  This coexpression only occurs in one other
disease entity, mantle cell lymphoma.  CLL B cells express relatively low
levels of surface-membrane immunoglobulin (compared with normal peripheral
blood B cells) and a single light chain (kappa or lambda).<Reference refidx="15"/>  CLL is diagnosed
by an absolute increase in lymphocytosis and/or bone marrow infiltration
coupled with the characteristic features of morphology and immunophenotype, which confirm the characteristic clonal population.
</Para><Para id="_6">The differential diagnosis must exclude hairy cell leukemia  and
Waldenström macroglobulinemia. (Refer to the PDQ summaries on <SummaryRef href="CDR0000062926" url="/types/leukemia/hp/hairy-cell-treatment-pdq">Hairy Cell Leukemia</SummaryRef> and <SummaryRef href="CDR0000062707" url="/types/lymphoma/hp/adult-nhl-treatment-pdq">Adult Non-Hodgkin Lymphoma Treatment</SummaryRef> for more information.)  Waldenström
macroglobulinemia has a natural history and therapeutic options similar to CLL,
with the exception of hyperviscosity syndrome associated with macroglobulinemia
as a result of elevated immunoglobulin M.  Prolymphocytic leukemia (PLL) is a
rare entity characterized by excessive prolymphocytes in the blood with a
typical phenotype that is positive for CD19, CD20, and surface-membrane
immunoglobulin and negative for CD5.  These patients demonstrate splenomegaly
and poor response to low-dose or high-dose chemotherapy.<Reference refidx="15"/><Reference refidx="33"/>  </Para><Para id="_310">Cladribine
(2-chlorodeoxyadenosine) appears to be an active agent (60% complete remission
rate) for patients with de novo B-cell prolymphocytic leukemia.<Reference refidx="34"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]   Alemtuzumab (campath-1H), an anti-CD52 humanized monoclonal antibody, has been used for 76 patients with T-cell prolymphocytic leukemia after failure of prior chemotherapy (usually pentostatin or cladribine) with a 51% response rate (95% confidence interval, 40%–63%) and median time to progression of 4.5 months (range,  0.1–45.4 months).<Reference refidx="35"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>] These response rates have been confirmed by other investigators.<Reference refidx="36"/> Patients with CLL who show prolymphocytoid transformation
maintain the classic CLL phenotype and have a worse prognosis than PLL
patients.  </Para><Para id="_305">Large granular lymphocyte (LGL)  leukemia is characterized by
lymphocytosis with a natural killer cell immunophenotype (CD2, CD16, and CD56)
or a T-cell immunophenotype (CD2, CD3, and CD8).<Reference refidx="37"/><Reference refidx="38"/><Reference refidx="39"/>  These patients often
have neutropenia and a history of rheumatoid arthritis.  The natural history is
indolent, often marked by anemia and splenomegaly.  This condition appears to
fit into the clinical spectrum of Felty syndrome.<Reference refidx="40"/>  A characteristic genetic finding in almost 50% of the patients with T-cell LGL involves mutations in the signal transducer and activator of the transcription 3 gene (<GeneName>STAT 3</GeneName>).<Reference refidx="41"/> Therapy includes
low doses of oral cyclophosphamide or methotrexate, cyclosporine, and treatment of
the bacterial infections acquired during severe neutropenia.<Reference refidx="37"/><Reference refidx="39"/><Reference refidx="42"/><Reference refidx="43"/>
</Para><SummarySection id="_301"><Title>Related Summaries</Title><Para id="_302">Other PDQ summaries containing information about CLL include the following:</Para><ItemizedList id="_303" Style="bullet"><ListItem><SummaryRef href="CDR0000062707" url="/types/lymphoma/hp/adult-nhl-treatment-pdq">Adult Non-Hodgkin Lymphoma Treatment</SummaryRef></ListItem><ListItem><SummaryRef href="CDR0000062926" url="/types/leukemia/hp/hairy-cell-treatment-pdq">Hairy Cell Leukemia</SummaryRef></ListItem></ItemizedList></SummarySection><ReferenceSection><Citation idx="1">American Cancer Society: Cancer Facts and Figures 2015. Atlanta, Ga: American Cancer Society, 2015. <ExternalRef xref="http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf">Available online</ExternalRef>. Last accessed April 1, 2015.</Citation><Citation idx="2" PMID="18358929">Dighiero G, Hamblin TJ: Chronic lymphocytic leukaemia. Lancet 371 (9617): 1017-29, 2008.</Citation><Citation idx="3" PMID="18216293">Hallek M, Cheson BD, Catovsky D, et al.: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111 (12): 5446-56, 2008.</Citation><Citation idx="4" PMID="19015397">Shanafelt TD, Kay NE, Jenkins G, et al.: B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood 113 (18): 4188-96, 2009.</Citation><Citation idx="5" PMID="18687638">Rawstron AC, Bennett FL, O'Connor SJ, et al.: Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 359 (6): 575-83, 2008.</Citation><Citation idx="6" PMID="18687646">Dighiero G: Monoclonal B-cell lymphocytosis--a frequent premalignant condition. N Engl J Med 359 (6): 638-40, 2008.</Citation><Citation idx="7" PMID="21876118">Fazi C, Scarfò L, Pecciarini L, et al.: General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood 118 (25): 6618-25, 2011.</Citation><Citation idx="8" PMID="19620484">Shanafelt TD, Kay NE, Rabe KG, et al.: Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol 27 (24): 3959-63, 2009.</Citation><Citation idx="9" PMID="19213679">Landgren O, Albitar M, Ma W, et al.: B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 360 (7): 659-67, 2009.</Citation><Citation idx="10" PMID="15205268">Ritgen M, Stilgenbauer S, von Neuhoff N, et al.: Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 104 (8): 2600-2, 2004.</Citation><Citation idx="11" PMID="15809449">Moreno C, Villamor N, Colomer D, et al.: Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 23 (15): 3433-8, 2005.</Citation><Citation idx="12" PMID="12194718">Khouri IF, Keating MJ, Saliba RM, et al.: Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 4 (3): 217-21, 2002.</Citation><Citation idx="13" PMID="12058231" MedlineID="22052470">Doney KC, Chauncey T, Appelbaum FR, et al.: Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant 29 (10): 817-23, 2002.</Citation><Citation idx="14" PMID="16043827">Pavletic SZ, Khouri IF, Haagenson M, et al.: Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol 23 (24): 5788-94, 2005.</Citation><Citation idx="15" PMID="7675049" MedlineID="95405434">Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 333 (16): 1052-7, 1995.</Citation><Citation idx="16" PMID="17299097">Wierda WG, O'Brien S, Wang X, et al.: Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109 (11): 4679-85, 2007.</Citation><Citation idx="17">Montserrat  E: CLL therapy: progress at last! Blood  105 (1): 2-3, 2005.</Citation><Citation idx="18" PMID="2757960" MedlineID="89335603">Catovsky D, Fooks J, Richards S: Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol 72 (2): 141-9, 1989.</Citation><Citation idx="19" PMID="9758577" MedlineID="98420299">Anaissie EJ, Kontoyiannis DP, O'Brien S, et al.: Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129 (7): 559-66, 1998.</Citation><Citation idx="20" PMID="10779422" MedlineID="20243301">Mauro FR, Foa R, Cerretti R, et al.: Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 95 (9): 2786-92, 2000.</Citation><Citation idx="21" PMID="11136261" MedlineID="21012240">Döhner H, Stilgenbauer S, Benner A, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 (26): 1910-6, 2000.</Citation><Citation idx="22" PMID="10477713" MedlineID="99408724">Hamblin TJ, Davis Z, Gardiner A, et al.: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94 (6): 1848-54, 1999.</Citation><Citation idx="23" PMID="10477712" MedlineID="99408723">Damle RN, Wasil T, Fais F, et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94 (6): 1840-7, 1999.</Citation><Citation idx="24" PMID="11733578" MedlineID="21590499">Rosenwald A, Alizadeh AA, Widhopf G, et al.: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194 (11): 1639-47, 2001.</Citation><Citation idx="25" PMID="11733577" MedlineID="21590498">Klein U, Tu Y, Stolovitzky GA, et al.: Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194 (11): 1625-38, 2001.</Citation><Citation idx="26" PMID="14726163">Orchard JA, Ibbotson RE, Davis Z, et al.: ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363 (9403): 105-11, 2004.</Citation><Citation idx="27" PMID="15329427">Rassenti LZ, Huynh L, Toy TL, et al.: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351 (9): 893-901, 2004.</Citation><Citation idx="28" PMID="16418492">Kröber A, Bloehdorn J, Hafner S, et al.: Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 24 (6): 969-75, 2006.</Citation><Citation idx="29" PMID="16344317">Byrd JC, Gribben JG, Peterson BL, et al.: Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 24 (3): 437-43, 2006.</Citation><Citation idx="30" PMID="15578683">Tsimberidou AM, Keating MJ: Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 103 (2): 216-28, 2005.</Citation><Citation idx="31" PMID="19114699">Tsimberidou AM, Wen S, McLaughlin P, et al.: Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 27 (6): 904-10, 2009.</Citation><Citation idx="32" PMID="9482521" MedlineID="98141625">DiGiuseppe JA, Borowitz MJ: Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol 25 (1): 6-10, 1998.</Citation><Citation idx="33" PMID="3487341" MedlineID="86243173">Melo JV, Catovsky D, Galton DA: The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. Br J Haematol 63 (2): 377-87, 1986.</Citation><Citation idx="34" PMID="8996122" MedlineID="97149314">Saven A, Lee T, Schlutz M, et al.: Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. J Clin Oncol 15 (1): 37-43, 1997.</Citation><Citation idx="35" PMID="11773171" MedlineID="21635074">Keating MJ, Cazin B, Coutré S, et al.: Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 20 (1): 205-13, 2002.</Citation><Citation idx="36" PMID="12180489" MedlineID="22167801">Dearden CE, Matutes E, Catovsky D: Alemtuzumab in T-cell malignancies. Med Oncol 19 (Suppl): S27-32, 2002.</Citation><Citation idx="37" PMID="16549811">Sokol L, Loughran TP Jr: Large granular lymphocyte leukemia. Oncologist 11 (3): 263-73, 2006.</Citation><Citation idx="38" PMID="8978299" MedlineID="97132940">Semenzato G, Zambello R, Starkebaum G, et al.: The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood 89 (1): 256-60, 1997.</Citation><Citation idx="39" PMID="21190991">Lamy T, Loughran TP Jr: How I treat LGL leukemia. Blood 117 (10): 2764-74, 2011.</Citation><Citation idx="40" PMID="7945496" MedlineID="95032245">Bowman SJ, Sivakumaran M, Snowden N, et al.: The large granular lymphocyte syndrome with rheumatoid arthritis. Immunogenetic evidence for a broader definition of Felty's syndrome. Arthritis Rheum 37 (9): 1326-30, 1994.</Citation><Citation idx="41" PMID="22591296">Koskela HL, Eldfors S, Ellonen P, et al.: Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 366 (20): 1905-13, 2012.</Citation><Citation idx="42" PMID="7919331" MedlineID="95002923">Loughran TP Jr, Kidd PG, Starkebaum G: Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 84 (7): 2164-70, 1994.</Citation><Citation idx="43" PMID="8068951" MedlineID="94348088">Dhodapkar MV, Li CY, Lust JA, et al.: Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood 84 (5): 1620-7, 1994.</Citation></ReferenceSection></SummarySection><SummarySection id="_7"><SectMetaData><SpecificDiagnosis ref="CDR0000037765">chronic lymphocytic leukemia</SpecificDiagnosis><SectionType>Stage explanation--legacy</SectionType></SectMetaData><Title>Stage Information for CLL</Title><Para id="_8">Staging is useful in chronic lymphocytic leukemia (CLL) to predict prognosis and also to stratify
patients to achieve comparisons for interpreting specific treatment results. 
Anemia and thrombocytopenia are the major adverse prognostic variables.
</Para><Para id="_9">CLL has no standard staging system.  The Rai
staging system and the Binet classification are presented below.<Reference refidx="1"/><Reference refidx="2"/>  A
National Cancer Institute (NCI)-sponsored working group has formulated standardized guidelines for
criteria related to eligibility, response, and toxic effects to be used in future clinical
trials in CLL.<Reference refidx="3"/>
</Para><SummarySection id="_10"><Title>Rai Staging System</Title><SummarySection id="_11"><Para id="_119"><Strong>Stage 0</Strong></Para><Para id="_12">Stage 0 CLL is characterized by absolute lymphocytosis (&gt;15,000/mm<Superscript>3</Superscript>) without adenopathy, hepatosplenomegaly, anemia, or
thrombocytopenia.
</Para></SummarySection><SummarySection id="_13"><Para id="_120"><Strong>Stage I</Strong></Para><Para id="_14">Stage I CLL is characterized by absolute lymphocytosis with
lymphadenopathy without hepatosplenomegaly, anemia, or thrombocytopenia.
</Para></SummarySection><SummarySection id="_15"><Para id="_121"><Strong>Stage II</Strong></Para><Para id="_16">Stage II CLL is characterized by absolute lymphocytosis with either
hepatomegaly or splenomegaly with or without lymphadenopathy.
</Para></SummarySection><SummarySection id="_17"><Para id="_122"><Strong>Stage III</Strong></Para><Para id="_18">Stage III CLL is characterized by absolute lymphocytosis and anemia
(hemoglobin &lt;11 g/dL) with or without lymphadenopathy, hepatomegaly, or
splenomegaly.
</Para></SummarySection><SummarySection id="_19"><Para id="_123"><Strong>Stage IV</Strong></Para><Para id="_20">Stage IV CLL is characterized by absolute lymphocytosis and
thrombocytopenia (&lt;100,000/mm<Superscript>3</Superscript>) with or without
lymphadenopathy, hepatomegaly, splenomegaly, or anemia.
</Para></SummarySection></SummarySection><SummarySection id="_21"><Title>Binet Classification</Title><Para id="_112"><Strong>Clinical stage A*</Strong></Para><Para id="_125">Clinical stage A CLL is characterized by no anemia or thrombocytopenia and fewer than three areas of
lymphoid involvement (Rai stages 0, I, and  II).</Para><Para id="_113"><Strong>Clinical stage B*</Strong></Para><Para id="_126">Clinical stage B CLL is characterized by no anemia or thrombocytopenia with three or more areas of
lymphoid involvement (Rai stages I and II).</Para><Para id="_114"><Strong>Clinical stage C</Strong></Para><Para id="_127">Clinical stage C CLL is characterized by anemia and/or thrombocytopenia regardless of the number of
areas of lymphoid enlargement (Rai stages III and IV).</Para><Para id="_128">*<Note>Lymphoid areas include cervical, axillary, inguinal, and spleen.</Note></Para><Para id="_29">The Binet classification integrates the number of nodal groups involved with
the disease with bone marrow failure.  Its major benefit derives from the
recognition of a predominantly splenic form of the disease, which may have a
better prognosis than in the Rai staging, and from recognition that the
presence of anemia or thrombocytopenia has a similar prognosis and does not
merit a separate stage.  Neither system separates immune from nonimmune causes
of cytopenia.  Patients with thrombocytopenia or anemia or both, which is caused by extensive marrow infiltration and impaired production (Rai III/IV, Binet C)
have a poorer prognosis than patients with immune cytopenias.<Reference refidx="4"/>  The
International Workshop on CLL has recommended
integrating the Rai and Binet systems as follows:  A(0), A(I), A(II); B(I),
B(II); and C(III), C(IV).<Reference refidx="5"/>  The NCI-sponsored working
group has published guidelines for the diagnosis and treatment of CLL in both
clinical trial and general practice settings.<Reference refidx="3"/>  Use of these systems allows
comparison of clinical results and establishment of therapeutic guidelines.
</Para></SummarySection><SummarySection id="_179"><Para id="_180"><Strong>Prognostic factors</Strong></Para><Para id="_181">New prognostic markers are now available to the clinician and investigator.<Reference refidx="6"/><Reference refidx="7"/>  The use of these markers to stratify patients in clinical trials, to  help assess the need for therapy, and to help select the type of therapy continues to evolve.  Prospective trials to verify and establish the role of these prognostic markers are ongoing.  No large multivariable analyses exist  as yet to test the relative power of these individual prognostic variables.<Reference refidx="8"/> Prognostic indices are under evaluation and will require prospective validation.<Reference refidx="9"/></Para><ItemizedList id="_182" Style="bullet" Compact="No"><ListItem>Immunoglobulin variable region heavy chain gene (IgV<Subscript>H</Subscript>) mutation.<Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/> The finding of significant numbers of mutations in this region is associated with a median survival in excess of 20 to 25 years.  The absence of mutations is associated with a median survival of 8 to 10 years.</ListItem><ListItem>ZAP-70. ZAP-70 has been proposed as a surrogate for the mutational status.<Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/><Reference refidx="18"/>   ZAP-70 positivity for previously untreated and asymptomatic patients (&gt;30%) is associated with a more unfavorable median survival (6–10 years), while a negative ZAP-70 is associated with a median survival of more than 15 years. A prospective evaluation  of these markers in a randomized study of fludarabine-based chemotherapy (<ProtocolRef href="CDR0000653680" nct_id="NCT00003764">E2997</ProtocolRef> [NCT00003764])  failed to show any difference in response rates, response duration, progression-free survival, or overall survival (OS).<Reference refidx="19"/></ListItem><ListItem>Chromosomal abnormalities by fluorescent <Emphasis>in situ</Emphasis> hybridization (FISH). FISH chromosomal abnormalities were associated with prognosis in retrospective and prospective studies and clonal evolution has been seen over time.<Reference refidx="20"/><Reference refidx="21"/><Reference refidx="22"/><Reference refidx="23"/> 13q- is favorable (with a 17-year median OS in a prospective study).<Reference refidx="23"/> Trisomy 12 and 11q- have less favorable prognoses (with a 9- to 11-year median OS in a prospective study).<Reference refidx="23"/>  In particular, 17p- is associated with mutated TP53 and with poor response rates and short duration of response to the standard therapeutic options.<Reference refidx="13"/> 17p- is associated with the most unfavorable prognosis (with a 7-year median OS in one prospective trial).<Reference refidx="19"/><Reference refidx="23"/><Reference refidx="24"/>  The combination of adverse cytogenetics such as 11q- or 17p- (suggesting a worse prognosis) with ZAP-70 negativity (suggesting a better prognosis) in the same patients resulted in a poor prognosis.<Reference refidx="18"/> These findings emphasize the need for prospective studies of combinations of these prognostic markers.<Reference refidx="8"/></ListItem><ListItem>CD38 immunophenotype.<Reference refidx="11"/><Reference refidx="25"/>  CD38 positivity (&gt;30%) correlates with a worse prognosis, but there is a 30% false-positive rate and a 50% false-negative rate using IgV<Subscript>H</Subscript> mutational status as the gold standard for prognosis.</ListItem></ItemizedList><Para id="_183">Other prognostic factors include:</Para><ItemizedList id="_184" Style="bullet" Compact="No"><ListItem>Stage.<Reference refidx="1"/><Reference refidx="2"/> (Refer to the <SummaryRef href="CDR0000062856#_10" url="/types/leukemia/hp/cll-treatment-pdq">Rai staging system</SummaryRef> section and the <SummaryRef href="CDR0000062856#_21" url="/types/leukemia/hp/cll-treatment-pdq">Binet classification</SummaryRef> section of this summary for more information.) </ListItem><ListItem>Lymphocyte doubling time (doubling of the white blood cell count in excess of 1 year implies a favorable prognosis).<Reference refidx="26"/></ListItem><ListItem>Beta-2-microglobulin (higher levels imply a worse prognosis).<Reference refidx="27"/></ListItem></ItemizedList></SummarySection><ReferenceSection><Citation idx="1" PMID="1139039" MedlineID="75184472">Rai KR, Sawitsky A, Cronkite EP, et al.: Clinical staging of chronic lymphocytic leukemia. Blood 46 (2): 219-34, 1975.</Citation><Citation idx="2" PMID="7237385" MedlineID="81209824">Binet JL, Auquier A, Dighiero G, et al.: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48 (1): 198-206, 1981.</Citation><Citation idx="3" PMID="18216293">Hallek M, Cheson BD, Catovsky D, et al.: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111 (12): 5446-56, 2008.</Citation><Citation idx="4" PMID="20736453">Moreno C, Hodgson K, Ferrer G, et al.: Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 116 (23): 4771-6, 2010.</Citation><Citation idx="5" PMID="2912362" MedlineID="89104126">Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia. Ann Intern Med 110 (3): 236-8, 1989.</Citation><Citation idx="6" PMID="18358929">Dighiero G, Hamblin TJ: Chronic lymphocytic leukaemia. Lancet 371 (9617): 1017-29, 2008.</Citation><Citation idx="7" PMID="17519887">Developments in the treatment of lymphoproliferative disorders: rising to the new challenges of CLL therapy. A report of a symposium presented during the 48th American Society of Hematology Annual Meeting and Exposition, December 8, 2006, Orlando, Florida. Clin Adv Hematol Oncol 5 (3 Suppl 5): 1-14; quiz 15-6, 2007.</Citation><Citation idx="8" PMID="16223776">Binet JL, Caligaris-Cappio F, Catovsky D, et al.: Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 107 (3): 859-61, 2006.</Citation><Citation idx="9" PMID="19090008">Shanafelt TD, Jenkins G, Call TG, et al.: Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 115 (2): 363-72, 2009.</Citation><Citation idx="10" PMID="10477713" MedlineID="99408724">Hamblin TJ, Davis Z, Gardiner A, et al.: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94 (6): 1848-54, 1999.</Citation><Citation idx="11" PMID="10477712" MedlineID="99408723">Damle RN, Wasil T, Fais F, et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94 (6): 1840-7, 1999.</Citation><Citation idx="12" PMID="11733578" MedlineID="21590499">Rosenwald A, Alizadeh AA, Widhopf G, et al.: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194 (11): 1639-47, 2001.</Citation><Citation idx="13" PMID="16344317">Byrd JC, Gribben JG, Peterson BL, et al.: Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 24 (3): 437-43, 2006.</Citation><Citation idx="14" PMID="18618518">Kharfan-Dabaja MA, Chavez JC, Khorfan KA, et al.: Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. Cancer 113 (5): 897-906, 2008.</Citation><Citation idx="15" PMID="12724482" MedlineID="22610364">Crespo M, Bosch F, Villamor N, et al.: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348 (18): 1764-75, 2003.</Citation><Citation idx="16" PMID="14726163">Orchard JA, Ibbotson RE, Davis Z, et al.: ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363 (9403): 105-11, 2004.</Citation><Citation idx="17" PMID="15329427">Rassenti LZ, Huynh L, Toy TL, et al.: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351 (9): 893-901, 2004.</Citation><Citation idx="18" PMID="16418492">Kröber A, Bloehdorn J, Hafner S, et al.: Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 24 (6): 969-75, 2006.</Citation><Citation idx="19" PMID="17283363">Grever MR, Lucas DM, Dewald GW, et al.: Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25 (7): 799-804, 2007.</Citation><Citation idx="20" PMID="11136261" MedlineID="21012240">Döhner H, Stilgenbauer S, Benner A, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 (26): 1910-6, 2000.</Citation><Citation idx="21" PMID="12149225">Kröber A, Seiler T, Benner A, et al.: V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100 (4): 1410-6, 2002.</Citation><Citation idx="22" PMID="2757960" MedlineID="89335603">Catovsky D, Fooks J, Richards S: Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol 72 (2): 141-9, 1989.</Citation><Citation idx="23" PMID="17008705">Shanafelt TD, Witzig TE, Fink SR, et al.: Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 24 (28): 4634-41, 2006.</Citation><Citation idx="24" PMID="17658394">Catovsky D, Richards S, Matutes E, et al.: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370 (9583): 230-9, 2007.</Citation><Citation idx="25" PMID="12406914">Ghia P, Guida G, Stella S, et al.: The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 101 (4): 1262-9, 2003.</Citation><Citation idx="26" PMID="3954968">Montserrat E, Sanchez-Bisono J, Viñolas N, et al.: Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 62 (3): 567-75, 1986.</Citation><Citation idx="27" PMID="2502891">Di Giovanni S, Valentini G, Carducci P, et al.: Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta Haematol 81 (4): 181-5, 1989.</Citation></ReferenceSection></SummarySection><SummarySection id="_30"><SectMetaData><SpecificDiagnosis ref="CDR0000037765">chronic lymphocytic leukemia</SpecificDiagnosis><SectionType>Treatment option overview--legacy</SectionType></SectMetaData><Title>Treatment Option Overview for CLL</Title><Para id="_32">Treatment of chronic lymphocytic leukemia (CLL) ranges from periodic
observation with treatment of infectious, hemorrhagic, or immunologic
complications to a variety of therapeutic options, including steroids,
alkylating agents, purine analogs, combination chemotherapy, monoclonal
antibodies, and transplant options.<Reference refidx="1"/>  Because this disease is generally not
curable, occurs in an elderly population, and often progresses slowly, it is
most often  treated in a conservative fashion.<Reference refidx="1"/>  In asymptomatic patients, treatment may be deferred until the patient becomes symptomatic as the disease progresses.  Since the rate of progression may vary from patient to patient, with long periods of stability and sometimes spontaneous regressions, frequent and careful observation is required to monitor the clinical course.<Reference refidx="2"/>  
</Para><Para id="_311">A meta-analysis of randomized
trials showed no survival benefit for immediate versus delayed therapy for
patients with early stage disease, nor for the use of combination regimens
incorporating an anthracycline compared with a single-agent alkylator for
advanced stage disease.<Reference refidx="3"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]  A variety of clinical
factors, including IgV<Subscript>H</Subscript>  mutation, chromosomal abnormalities by fluorescent <Emphasis>in situ</Emphasis> hybridization  analysis or cytogenetics, beta-2-microglobulin, and lymphocyte doubling time may be helpful in predicting progression of
disease.<Reference refidx="1"/></Para><Para id="_33">Infectious complications in advanced disease are in part a consequence of the
hypogammaglobulinemia and the inability to mount a humoral defense against
bacterial or viral agents.  Herpes zoster represents a frequent viral infection
in these patients, but infections with <Emphasis>Pneumocystis carinii</Emphasis> and <Emphasis>Candida
albicans</Emphasis> may also occur.  The early recognition of infections and the
institution of appropriate therapy are critical to the long-term survival of
these patients.  A randomized study of intravenous immunoglobulin (400
mg/kg every 3 weeks for 1 year) in patients with CLL and
hypogammaglobulinemia produced significantly fewer bacterial infections and a
significant delay in onset of first infection during the study period.<Reference refidx="4"/> 
There was, however,  no effect on survival. Routine chronic administration of
intravenous immunoglobulin is expensive, and the long-term benefit (&gt;1
year) is unproven.<Reference refidx="5"/><Reference refidx="6"/>
</Para><Para id="_34">Second malignancies and treatment-induced acute leukemias may also occur in a
small percentage of patients.<Reference refidx="7"/>  Transformation of CLL to diffuse large cell
lymphoma (Richter syndrome) carries a poor prognosis with a median survival
of less than 1 year, though 20% of the patients may live more than 5 years
after aggressive combination chemotherapy.<Reference refidx="8"/>  (Refer to the PDQ summary on  
<SummaryRef href="CDR0000062707" url="/types/lymphoma/hp/adult-nhl-treatment-pdq">Adult Non-Hodgkin Lymphoma Treatment</SummaryRef> for more information.)
</Para><Para id="_35">Autoimmune hemolytic anemia and/or thrombocytopenia can occur in patients with
any stage of CLL.<Reference refidx="9"/>  Initial therapy involves corticosteroids with or without
alkylating agents (fludarabine can worsen the hemolytic anemia).  It is
frequently advisable to control the autoimmune destruction with
corticosteroids, if possible, prior to administering marrow-suppressive
chemotherapy because such patients may be difficult to transfuse successfully
with either red blood cells or platelets.  Alternate therapies include
high-dose immune globulin, rituximab, cyclosporine, azathioprine, splenectomy, and low-dose radiation therapy to
the spleen.<Reference refidx="10"/><Reference refidx="11"/>  Tumor lysis syndrome is an uncommon complication (presenting
in 1 out of 300 patients)  of chemotherapy for patients with bulky disease.<Reference refidx="12"/>
</Para><Para id="_36">About 1% of morphologic CLL cases express T-cell markers (CD4 and CD7) and have
clonal rearrangements of their T-cell receptor genes.  These patients have a
higher frequency of skin lesions, more variable lymphocyte shape, and shorter
median survival (13 months) with minimal responses to chemotherapy.<Reference refidx="13"/>
</Para><Para id="_304">Computed tomographic (CT) scans have a very limited role in following patients after completion of treatment; the decision to treat for relapse was determined by CT scan or ultrasound in only 2  of 176 patients in three  prospective trials for the German CLL Study Group.<Reference refidx="14"/></Para><ReferenceSection><Citation idx="1" PMID="21220603">Gribben JG, O'Brien S: Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 29 (5): 544-50, 2011.</Citation><Citation idx="2" PMID="19387007">Del Giudice I, Chiaretti S, Tavolaro S, et al.: Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases. Blood 114 (3): 638-46, 2009.</Citation><Citation idx="3" PMID="10340906" MedlineID="99270754">Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 91 (10): 861-8, 1999.</Citation><Citation idx="4" PMID="2901668" MedlineID="88334627">Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. N Engl J Med 319 (14): 902-7, 1988.</Citation><Citation idx="5" PMID="2492832" MedlineID="89134943">Griffiths H, Brennan V, Lea J, et al.: Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 73 (2): 366-8, 1989.</Citation><Citation idx="6" PMID="1904989" MedlineID="91270321">Weeks JC, Tierney MR, Weinstein MC: Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 325 (2): 81-6, 1991.</Citation><Citation idx="7" PMID="17910629">Maddocks-Christianson K, Slager SL, Zent CS, et al.: Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol 139 (3): 398-404, 2007.</Citation><Citation idx="8" PMID="8410123" MedlineID="94015219">Robertson LE, Pugh W, O'Brien S, et al.: Richter's syndrome: a report on 39 patients. J Clin Oncol 11 (10): 1985-9, 1993.</Citation><Citation idx="9" PMID="10779422" MedlineID="20243301">Mauro FR, Foa R, Cerretti R, et al.: Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 95 (9): 2786-92, 2000.</Citation><Citation idx="10" PMID="7675049" MedlineID="95405434">Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 333 (16): 1052-7, 1995.</Citation><Citation idx="11" PMID="19391041">Kaufman M, Limaye SA, Driscoll N, et al.: A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia. Leuk Lymphoma 50 (6): 892-9, 2009.</Citation><Citation idx="12" PMID="9667245" MedlineID="98329819">Cheson BD, Frame JN, Vena D, et al.: Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 16 (7): 2313-20, 1998.</Citation><Citation idx="13" PMID="7620169" MedlineID="95345468">Hoyer JD, Ross CW, Li CY, et al.: True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases. Blood 86 (3): 1163-9, 1995.</Citation><Citation idx="14" PMID="21139079">Eichhorst BF, Fischer K, Fink AM, et al.: Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. Blood 117 (6): 1817-21, 2011.</Citation></ReferenceSection></SummarySection><SummarySection id="_38"><SectMetaData><SpecificDiagnosis ref="CDR0000037766">stage 0 chronic lymphocytic leukemia</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage 0 CLL</Title><Para id="_40">Because of the indolent nature of stage 0 chronic lymphocytic leukemia (CLL),
treatment is not indicated.<Reference refidx="1"/>  The French Cooperative Group on CLL randomly assigned 1,535 patients with previously untreated stage A
disease to receive either chlorambucil or no immediate treatment and found no
survival advantage for immediate treatment with chlorambucil.<Reference refidx="2"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]  A meta-analysis of six trials of immediate versus deferred
therapy with chlorambucil (including the aforementioned trial by the French
Cooperative Group) showed no difference in overall survival at 10
years.<Reference refidx="3"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]  Whether immediate therapy with the
nucleoside analogs or other newer strategies will be superior to a watchful
waiting approach is uncertain.
</Para><SummarySection id="_TrialSearch_38_sid_4"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_38_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=37766&amp;tt=1&amp;format=2&amp;cn=1">stage 0 chronic lymphocytic leukemia</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_38_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1">Casper JT: Prognostic features of early chronic lymphocytic leukaemia. International Workshop on CLL. Lancet  2 (8669): 968-9, 1989.</Citation><Citation idx="2" PMID="9593789" MedlineID="98242980">Dighiero G, Maloum K, Desablens B, et al.: Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 338 (21): 1506-14, 1998.</Citation><Citation idx="3" PMID="10340906" MedlineID="99270754">Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 91 (10): 861-8, 1999.</Citation></ReferenceSection></SummarySection><SummarySection id="_56"><SectMetaData><SpecificDiagnosis ref="CDR0000038467">stage I chronic lymphocytic leukemia</SpecificDiagnosis><SpecificDiagnosis ref="CDR0000038479">stage II chronic lymphocytic leukemia</SpecificDiagnosis><SpecificDiagnosis ref="CDR0000038490">stage III chronic lymphocytic leukemia</SpecificDiagnosis><SpecificDiagnosis ref="CDR0000038501">stage IV chronic lymphocytic leukemia</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage I, II, III, and IV CLL</Title><Para id="_276">Several decades of large, randomized, prospective trials of previously untreated patients have demonstrated statistically significant improvements in response rates, event-free survival (EFS), and progression-free survival (PFS) with comparison of combinations of drugs versus single-agent alkylators,<Reference refidx="1"/><Reference refidx="2"/> but only two trials have shown statistically significant improvement in overall survival (OS).<Reference refidx="3"/><Reference refidx="4"/></Para><Para id="_277">The first trial, a comparison of chlorambucil versus fludarabine, after 15 years of median follow-up, showed improved median OS for patients on the fludarabine regimen at 63 months versus 59 months (<Emphasis>P </Emphasis>= .04), and an improved percentage of patients were alive at 8 years (31% vs. 19%, <Emphasis>P </Emphasis>= .04).<Reference refidx="3"/><Reference refidx="5"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] </Para><Para id="_312">The second trial, which had 817 patients, compared FCR (fludarabine + cyclophosphamide + rituximab) versus FC (fludarabine + cyclophosphamide) with a median follow-up of 38 months and showed improved OS at 3 years for the rituximab combination (i.e., 87% vs. 83%, <Emphasis>P</Emphasis> = .01.<Reference refidx="4"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] Yet neither fludarabine nor FCR has been compared in a randomized study against watchful waiting in asymptomatic or minimally affected patients.</Para><Para id="_278">The improvements in response rates from more intensive regimens have maximized the clearance of minimal residual disease (MRD).  In one prospective trial of 493 patients, clearance of MRD was an independent predictor of OS by multivariate analysis.<Reference refidx="6"/> The surrogate endpoint of such clearance of residual disease, while prognostic,<Reference refidx="6"/><Reference refidx="7"/>  has not been shown to improve survival in a randomized prospective trial; the necessary study would take patients who fail to completely clear the marrow with induction therapy and randomly assign them to further alternative treatment versus the same treatment later at relapse, looking at OS as the primary endpoint.<Reference refidx="1"/><Reference refidx="2"/>  </Para><Para id="_313">The sequencing of the following treatment options cannot be determined from the current set of completed clinical trials.  When patients become symptomatic or require treatment, FCR has become the most frequently chosen option outside of a clinical trial, mostly on the basis of the previously described prospective study.<Reference refidx="4"/></Para><Para id="_314"><Strong>Treatment options:</Strong></Para><Para id="_185">Note: Standard options are roughly ordered by level of toxic effects, starting with the least toxic options. More recently discovered options are mentioned at the end of the list.</Para><OrderedList id="_109" Style="Arabic" Compact="No"><ListItem>Observation in asymptomatic or minimally affected patients.<Reference refidx="8"/> Outside of the context of a clinical trial, treatment for asymptomatic or minimally affected patients with chronic lymphocytic leukemia (CLL) is observation. No data exist as yet to suggest any harm with a delay in therapy until the patient becomes symptomatic or develops serious cytopenias despite growth factor support.  Because the rate of progression may vary from patient to patient, with long periods of stability and sometimes spontaneous regressions, frequent and careful observation is required to monitor the clinical course.
</ListItem><ListItem>Rituximab is a murine anti-CD20 monoclonal antibody.<Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/> When used alone, higher doses of rituximab or increased frequency or duration of therapy is required for comparable responses to those seen for other indolent lymphomas.</ListItem><ListItem>Ofatumomab is a human anti-CD20 monoclonal antibody.<Reference refidx="14"/> A trial of 138 patients, who were previously treated with fludarabine and alemtuzumab, showed overall response rates around 50% in patients refractory to fludarabine and with prior exposure to rituximab.<Reference refidx="14"/><Reference refidx="15"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]</ListItem><ListItem>Obinutuzumab is a human anti-CD20 monoclonal antibody. In a randomized prospective trial (<ProtocolRef href="CDR0000659405" nct_id="NCT01010061">NCT01010061)</ProtocolRef>, 781 previously untreated patients with coexisting medical problems were randomly assigned to chlorambucil and obinutuzumab versus chlorambucil and  rituximab versus chlorambucil alone.<Reference refidx="16"/> The median PFS was best for the obinutuzumab arm (26.7 months) versus the rituximab arm (16.3 months)  versus chlorambucil alone (11.1 months ) (hazard ratio [HR], 0.18; 95% confidence interval [CI], 0.13–0.24; <Emphasis>P</Emphasis> &lt; .001) for obinutuzumab and chlorambucil versus chlorambucil alone;  for rituximab and chlorambucil versus chlorambucil alone [HR, 0.44; 95% CI, 0.34–0.57; <Emphasis>P</Emphasis> &lt; .001]. The 2-year OS was significantly improved for the obinutuzumab arm (91%) versus chlorambucil alone (80%) (HR, 0.41; 95% CI, 0.23–0.74, <Emphasis>P</Emphasis> = .002). Patients who received obinutuzumab did not have improved survival compared with those who received rituximab alone.<Reference refidx="16"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] </ListItem><ListItem>Idelalisib is an oral inhibitor of the delta isoform of the phosphatidylinositol 3-kinase, which is located in the B-cell receptor-signaling cascade. In a randomized, double-blind, prospective trial (<ProtocolRef href="CDR0000727348" nct_id="NCT01539512">NCT01539512</ProtocolRef>), 220 patients treated mainly with fludarabine-based regimens and who had coexisting medical problems, such as renal dysfunction, received rituximab and idelalisib versus rituximab and placebo.<Reference refidx="17"/> With a median follow-up of less than 1 year, the PFS rate at 24 weeks favored the rituximab and  idelalisib arm (93%) versus the rituximab and placebo arm (46%) (HR, 0.15; 95% CI, 0.08–0.28; <Emphasis>P</Emphasis> &lt; .001), and the OS rate at 1 year was significantly better for the rituximab and idelalisib arm (92%)  versus the  rituximab and placebo arm (80%) (HR, 0.28; 95% CI, 0.09–0.86; <Emphasis>P</Emphasis> = .02).<Reference refidx="17"/>[<LOERef href="CDR0000335106">Level of evidence: 1iA</LOERef>]</ListItem><ListItem>Ibrutinib is a selective irreversible inhibitor of Bruton tyrosine kinase, a signaling molecule located upstream in the B-cell receptor-signaling cascade.  Trials of previously untreated patients and of patients with relapsed or refractory CLL showed  durable responses to the oral agent in phase I and II studies.<Reference refidx="18"/><Reference refidx="19"/>[<LOERef href="CDR0000335158">Level of evidence: 3iiiDiii</LOERef>] A phase Ib–II trial (<ProtocolRef href="CDR0000671279" nct_id="NCT01105247">NCT01105247</ProtocolRef>) of 85 patients with relapsed or refractory CLL showed a 26-month PFS rate of 75% and included patients  with 17p- or unmutated IgVH fluorescence <Emphasis>in situ</Emphasis> hybridization testing.<Reference refidx="20"/>[<LOERef href="CDR0000335158">Level of evidence: 3iiiDiii</LOERef>]</ListItem><ListItem>Oral alkylating agents with or without corticosteroids.<Reference refidx="21"/>  The French
Cooperative Group on CLL randomly assigned 1,535 patients with
previously untreated stage A disease to receive either chlorambucil or no
immediate treatment and found no survival advantage for chlorambucil.<Reference refidx="22"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]  A meta-analysis of six trials of immediate versus deferred
therapy with chlorambucil  (including the aforementioned trial by the French
Cooperative Group) showed no difference in OS at 10
years.<Reference refidx="8"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]  </ListItem><ListItem>Fludarabine, 2-chlorodeoxyadenosine, or pentostatin as seen in the CLB-9011 trial, for example.<Reference refidx="23"/><Reference refidx="24"/><Reference refidx="25"/><Reference refidx="26"/>
<Reference refidx="27"/><Reference refidx="28"/> Several randomized trials have compared the purine analogs with chlorambucil;
with cyclophosphamide, doxorubicin, and prednisone; or with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in previously untreated
patients.<Reference refidx="5"/><Reference refidx="29"/><Reference refidx="30"/><Reference refidx="31"/><Reference refidx="32"/> All of these trials showed
higher or equivalent response rates for the purine analog, and most showed an improvement in
PFS; one reached significance in OS favoring fludarabine.<Reference refidx="3"/><Reference refidx="29"/><Reference refidx="30"/><Reference refidx="31"/><Reference refidx="32"/><Reference refidx="33"/>[<LOERef href="CDR0000335131">Level of evidence: 1iiDiii</LOERef>]      <Para id="_315">A comparison of chlorambucil versus fludarabine, after 15 years' median follow-up, showed patients with  improved median OS with fludarabine at 63 versus 59 months (<Emphasis>P</Emphasis> = .04) and an improved percentage of patients alive at 8 years (31% vs. 19%, <Emphasis>P </Emphasis>= .04).<Reference refidx="3"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] All
of the trials demonstrated higher toxic effects with the purine analogs,
especially granulocytopenic infections, herpes infections, autoimmune
hemolytic anemia, and persistent thrombocytopenia.<Reference refidx="34"/>
The increased risk of infection may persist for months or years after treatment with a purine analog.<Reference refidx="33"/><Reference refidx="35"/>  </Para><Para id="_316">Although empiric evidence is lacking, some investigators recommend prophylaxis with trimethoprim-sulfa during therapy and for 6 to 12 months afterwards to prevent pneumocystis infection.  In a similar way, other investigators employ prophylaxis (e.g., acyclovir) for the herpes viruses.<Reference refidx="35"/> Purine analogs cause less hair loss or nausea than combination chemotherapy, including alkylators and anthracyclines.<Reference refidx="31"/></Para></ListItem><ListItem>Bendamustine is a cytotoxic agent with bifunctional properties of an alkylator and a purine analog.<Reference refidx="36"/> In previously treated and untreated patients, bendamustine with rituximab has shown response rates around 70% to 90%.<Reference refidx="37"/><Reference refidx="38"/>[<LOERef href="CDR0000335158">Level of evidence: 3iiiDiii</LOERef>] <Para id="_279">In a randomized comparison with chlorambucil in 319 previously treated patients, bendamustine showed a  better response rate (68% vs. 31%, <Emphasis>P</Emphasis> &lt; .0001) and PFS (21.6 months vs. 8 months) with a median follow-up of 35 months.<Reference refidx="39"/>[<LOERef href="CDR0000335131">Level of evidence: 1iiDiii</LOERef>]  The German CLL Study Group is comparing bendamustine plus rituximab versus FCR as first-line therapy in patients with CLL who require therapy.<Reference refidx="37"/></Para></ListItem><ListItem> Lenalidomide is an oral immunomodulatory agent with response rates over 50%, with or without rituximab, for patients with previously treated and untreated disease.<Reference refidx="40"/><Reference refidx="41"/><Reference refidx="42"/><Reference refidx="43"/><Reference refidx="44"/><Reference refidx="45"/>[<LOERef href="CDR0000587991">Level of evidence:  3iiiDiv</LOERef>] Prolonged, lower-dose approaches and attention to prevention of tumor lysis syndrome are suggested with this agent.<Reference refidx="40"/><Reference refidx="46"/> Combination therapy and long-term toxicities from using lenalidomide (such as increased myelodysplasia, as seen in myeloma patients) remain undefined for patients with CLL.</ListItem><ListItem>Combination chemotherapy. A trial of 817 patients comparing FCR versus FC with a median follow-up of 38 months showed improved OS at 3 years for the rituximab combination (87% vs. 83%, <Emphasis>P</Emphasis> = .01).<Reference refidx="4"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]  FCR has never been compared with watchful waiting up front in asymptomatic or minimally affected patients.  The improvements in response rates from more intensive regimens have maximized the clearance of MRD.  However, the surrogate endpoint of MRD clearance has not been proven to be a valid surrogate for improved survival in a randomized,  prospective trial; the necessary study would take patients who fail to completely clear the marrow with induction therapy and randomly assign them to further alternative treatment versus the same treatment later at relapse looking at OS as the primary endpoint.<Reference refidx="1"/><Reference refidx="2"/> A cumulative incidence of 6% to 8 % for myelodysplasia is seen at 5 to 7 years in patients who received fludarabine plus cyclophosphamide, with or without rituximab.<Reference refidx="47"/><Reference refidx="48"/><Para id="_341">Other combination chemotherapy regimens include the following:</Para><ItemizedList id="_103" Style="bullet"><ListItem>Fludarabine plus cyclophosphamide plus rituximab.<Reference refidx="4"/><Reference refidx="49"/><Reference refidx="50"/><Reference refidx="51"/><Reference refidx="52"/></ListItem><ListItem>Fludarabine plus rituximab as seen in the <ProtocolRef href="CDR0000066128" nct_id="NCT00003248">CLB-9712</ProtocolRef> and CLB-9011 trials.<Reference refidx="53"/></ListItem><ListItem>Fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide plus rituximab.<Reference refidx="4"/><Reference refidx="54"/></ListItem><ListItem>Pentostatin plus cyclophosphamide plus rituximab as seen in the <ProtocolRef href="CDR0000528384" nct_id="NCT00201721">MAYO-MC0183</ProtocolRef> trial, for example.<Reference refidx="55"/><Reference refidx="56"/></ListItem><ListItem>Ofatumumab plus fludarabine plus cyclophosphamide.<Reference refidx="57"/></ListItem><ListItem>CVP: cyclophosphamide plus vincristine plus
prednisone.<Reference refidx="58"/></ListItem><ListItem>CHOP: cyclophosphamide plus doxorubicin plus vincristine plus
prednisone.<Reference refidx="59"/></ListItem><ListItem>        Fludarabine plus cyclophosphamide versus fludarabine  as seen in the <ProtocolRef href="CDR0000653680" nct_id="NCT00003764">E2997</ProtocolRef> trial [NCT00003764] and the  <ProtocolRef href="CDR0000067454" nct_id="NCT00004218">LRF-CLL4</ProtocolRef> trial, for example.<Reference refidx="60"/><Reference refidx="61"/></ListItem><ListItem>Fludarabine plus chlorambucil as seen in the CLB-9011 trial, for example.<Reference refidx="62"/></ListItem></ItemizedList>    <Para id="_104">A meta-analysis of ten trials comparing combination chemotherapy (before the availability of rituximab) with   
chlorambucil alone showed no difference in OS at 5   
years.<Reference refidx="8"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]
</Para></ListItem><ListItem>Involved-field radiation therapy.  Relatively low doses of radiation therapy will
affect an excellent response for months or years.  Sometimes radiation therapy to one
nodal area or the spleen will result in abscopal effect (i.e., the shrinkage of lymph
node tumors in untreated sites).
</ListItem><ListItem> Alemtuzumab, the monoclonal antibody directed at CD52, shows activity in the setting of chemotherapy-resistant disease or high-risk untreated patients with 17p deletion or p53 mutation.<Reference refidx="63"/><Reference refidx="64"/><Reference refidx="65"/> As a single agent, the subcutaneous route of delivery  for alemtuzumab is preferred to the intravenous route in patients because of the  similar efficacy and decreased adverse effects, including less acute allergic reactions that were shown in some  nonrandomized reports.<Reference refidx="65"/><Reference refidx="66"/><Reference refidx="67"/><Reference refidx="68"/><Reference refidx="69"/> <Para id="_308">In a combination regimen, subcutaneous alemtuzumab plus fludarabine (with or without cyclophosphamide) or intravenous alemtuzumab plus alkylating agents have resulted in excess infectious toxicities and death, with no compensatory improvement in efficacy in phase II trials.<Reference refidx="70"/><Reference refidx="71"/><Reference refidx="72"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]  </Para><Para id="_343">In a randomized prospective study, 335 previously treated patients received intravenous alemtuzumab plus fludarabine versus fludarabine alone; with a median follow-up of 30 months, the combination of fludarabine plus intravenous alemtuzumab had better PFS, with a median of 23.7 months versus 16.5 months (HR, 0.61; 95% CI, 0.47–0.80; <Emphasis>P</Emphasis> = .0003); and better OS, with a median not reached, versus 52.9 months (HR, 0.65; 95% CI, 0.45–0.94; <Emphasis>P</Emphasis> = .021).<Reference refidx="73"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] Profound and long-lasting immunosuppression has been seen, which mandates monitoring for reactivation of cytomegalovirus and prophylaxis for pneumocystis and herpes virus infections.<Reference refidx="74"/><Reference refidx="75"/> Antibiotic prophylaxis includes trimethoprim and sulfamethoxazole, itraconazole, and acyclovir (or ganciclovir) for asymptomatic cytomegalovirus viremia.</Para></ListItem><ListItem> Bone marrow and peripheral stem cell transplantations are under clinical
evaluation.<Reference refidx="76"/><Reference refidx="77"/><Reference refidx="78"/><Reference refidx="79"/><Reference refidx="80"/><Reference refidx="81"/><Reference refidx="82"/>
In a prospective randomized trial, 241 previously untreated patients younger than 66 years with advanced-stage disease received induction therapy with a CHOP-based regimen followed by fludarabine.<Reference refidx="83"/> Complete responders (105 patients) were randomly assigned to undergo autologous stem cell transplantation (ASCT) or observation, while the other 136 patients were randomly assigned to receive dexamethasone, high-dose aracytin, and cisplatin reinduction followed by either ASCT or fludarabine plus cyclophosphamide.  Although the 3-year EFS favored ASCT in complete responders, there was no difference in OS in any of the randomized comparisons.<Reference refidx="83"/>[<LOERef href="CDR0000335128">Level of evidence: 1iiDi</LOERef>]
<Para id="_318">Patients  with adverse prognostic factors are very likely to die from CLL.  These patients are candidates for clinical trials that employ high-dose chemotherapy and immunotherapy with myeloablative or nonmyeloablative allogeneic peripheral stem cell transplantation.<Reference refidx="76"/><Reference refidx="77"/><Reference refidx="78"/><Reference refidx="79"/><Reference refidx="80"/><Reference refidx="81"/><Reference refidx="84"/><Reference refidx="85"/><Reference refidx="86"/><Reference refidx="87"/><Reference refidx="88"/><Reference refidx="89"/><Reference refidx="90"/><Reference refidx="91"/> Although most patients who attain complete remission after ASCT eventually relapse,<Reference refidx="82"/> a survival plateau for allogeneic stem cell support suggests an additional graft-versus-leukemia effect.<Reference refidx="91"/> A series (<ProtocolRef href="CDR0000455092" nct_id="NCT00281983">NCT00281983</ProtocolRef>) of 90 patients with relapsed or refractory CLL who underwent ASCT reported a 58% 6-year OS rate and a 38% 6-year EFS rate, which included those patients with the worst prognostic factors (such as <GeneName>TP53</GeneName> gene mutation).<Reference refidx="92"/>[<LOERef href="CDR0000593395">Level of evidence: 3iiiD</LOERef>]</Para></ListItem><ListItem>Autologous T-cells were modified by a lentiviral vector to incorporate antigen receptor specificity for the B-cell antigen CD19 and then infused into a previously treated patient.<Reference refidx="93"/>  A dramatic response lasting 6 months has prompted larger trials of this concept.<Reference refidx="93"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>] Ongoing clinical trials are testing the concept of T-cells directed at specific antigen targets with engineered chimeric–antigen receptors (termed CARs).<Reference refidx="94"/></ListItem></OrderedList><SummarySection id="_TrialSearch_56_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_56_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38467&amp;tt=1&amp;format=2&amp;cn=1">stage I chronic lymphocytic leukemia</ExternalRef>, <ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38479&amp;tt=1&amp;format=2&amp;cn=1">stage II chronic lymphocytic leukemia</ExternalRef>, <ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38490&amp;tt=1&amp;format=2&amp;cn=1">stage III chronic lymphocytic leukemia</ExternalRef> and <ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38501&amp;tt=1&amp;format=2&amp;cn=1">stage IV chronic lymphocytic leukemia</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_56_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="17519887">Developments in the treatment of lymphoproliferative disorders: rising to the new challenges of CLL therapy. A report of a symposium presented during the 48th American Society of Hematology Annual Meeting and Exposition, December 8, 2006, Orlando, Florida. Clin Adv Hematol Oncol 5 (3 Suppl 5): 1-14; quiz 15-6, 2007.</Citation><Citation idx="2" PMID="16204307">Montserrat E, Moreno C, Esteve J, et al.: How I treat refractory CLL. Blood 107 (4): 1276-83, 2006.</Citation><Citation idx="3">Rai KR, Peterson, Frederick R. Appelbaum BL, Appelbaum FR, et al.: Long-term survival analysis of the North American Intergroup Study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with chronic lymphocytic leukemia (CLL). [Abstract] Blood  114 (22): A-536, 2009.</Citation><Citation idx="4" PMID="20888994">Hallek M, Fischer K, Fingerle-Rowson G, et al.: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376 (9747): 1164-74, 2010.</Citation><Citation idx="5" PMID="11114313" MedlineID="20550367">Rai KR, Peterson BL, Appelbaum FR, et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343 (24): 1750-7, 2000.</Citation><Citation idx="6" PMID="22331940">Böttcher S, Ritgen M, Fischer K, et al.: Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30 (9): 980-8, 2012.</Citation><Citation idx="7" PMID="24705492">Strati P, Keating MJ, O'Brien SM, et al.: Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 123 (24): 3727-32, 2014.</Citation><Citation idx="8" PMID="10340906" MedlineID="99270754">Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 91 (10): 861-8, 1999.</Citation><Citation idx="9" PMID="12721266">Mavromatis B, Cheson BD: Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol 21 (9): 1874-81, 2003.</Citation><Citation idx="10" PMID="11304768" MedlineID="21201276">O'Brien SM, Kantarjian H, Thomas DA, et al.: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19 (8): 2165-70, 2001.</Citation><Citation idx="11" PMID="11304767" MedlineID="21201275">Byrd JC, Murphy T, Howard RS, et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19 (8): 2153-64, 2001.</Citation><Citation idx="12" PMID="12721250">Hainsworth JD, Litchy S, Barton JH, et al.: Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21 (9): 1746-51, 2003.</Citation><Citation idx="13" PMID="18754025">Castro JE, Sandoval-Sus JD, Bole J, et al.: Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 22 (11): 2048-53, 2008.</Citation><Citation idx="14" PMID="20194866">Wierda WG, Kipps TJ, Mayer J, et al.: Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28 (10): 1749-55, 2010.</Citation><Citation idx="15" PMID="21856867">Wierda WG, Padmanabhan S, Chan GW, et al.: Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 118 (19): 5126-9, 2011.</Citation><Citation idx="16" PMID="24401022">Goede V, Fischer K, Busch R, et al.: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370 (12): 1101-10, 2014.</Citation><Citation idx="17" PMID="24450857">Furman RR, Sharman JP, Coutre SE, et al.: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370 (11): 997-1007, 2014.</Citation><Citation idx="18" PMID="23045577">Advani RH, Buggy JJ, Sharman JP, et al.: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31 (1): 88-94, 2013.</Citation><Citation idx="19" PMID="24332241">O'Brien S, Furman RR, Coutre SE, et al.: Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 15 (1): 48-58, 2014.</Citation><Citation idx="20" PMID="23782158">Byrd JC, Furman RR, Coutre SE, et al.: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369 (1): 32-42, 2013.</Citation><Citation idx="21" PMID="2180493" MedlineID="90199061">A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood 75 (7): 1422-5, 1990.</Citation><Citation idx="22" PMID="9593789" MedlineID="98242980">Dighiero G, Maloum K, Desablens B, et al.: Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 338 (21): 1506-14, 1998.</Citation><Citation idx="23" PMID="8400226" MedlineID="94003207">O'Brien S, Kantarjian H, Beran M, et al.: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82 (6): 1695-700, 1993.</Citation><Citation idx="24" PMID="7707127" MedlineID="95222329">Tallman MS, Hakimian D, Zanzig C, et al.: Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 13 (4): 983-8, 1995.</Citation><Citation idx="25" PMID="7884417" MedlineID="95190504">Saven A, Lemon RH, Kosty M, et al.: 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 13 (3): 570-4, 1995.</Citation><Citation idx="26" PMID="2784491" MedlineID="89177424">Dillman RO, Mick R, McIntyre OR: Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B. J Clin Oncol 7 (4): 433-8, 1989.</Citation><Citation idx="27" PMID="11504743" MedlineID="21396211">Morrison VA, Rai KR, Peterson BL, et al.: Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 19 (16): 3611-21, 2001.</Citation><Citation idx="28" PMID="16551966">Robak T, Blonski JZ, Gora-Tybor J, et al.: Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 108 (2): 473-9, 2006.</Citation><Citation idx="29" PMID="11023504" MedlineID="20477835">Robak T, Bloński JZ, Kasznicki M, et al.: Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 96 (8): 2723-9, 2000.</Citation><Citation idx="30" PMID="8676625" MedlineID="96225350">Johnson S, Smith AG, Löffler H, et al.: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 347 (9013): 1432-8, 1996.</Citation><Citation idx="31" PMID="11588025" MedlineID="21471953">Leporrier M, Chevret S, Cazin B, et al.: Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98 (8): 2319-25, 2001.</Citation><Citation idx="32" PMID="19605849">Eichhorst BF, Busch R, Stilgenbauer S, et al.: First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 114 (16): 3382-91, 2009.</Citation><Citation idx="33" PMID="16856041">Steurer M, Pall G, Richards S, et al.: Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database Syst Rev 3: CD004270, 2006.</Citation><Citation idx="34" PMID="18055869">Dearden C, Wade R, Else M, et al.: The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 111 (4): 1820-6, 2008.</Citation><Citation idx="35" PMID="11932906" MedlineID="21929480">Perkins JG, Flynn JM, Howard RS, et al.: Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 94 (7): 2033-9, 2002.</Citation><Citation idx="36" PMID="18172283">Leoni LM, Bailey B, Reifert J, et al.: Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14 (1): 309-17, 2008.</Citation><Citation idx="37" PMID="21844497">Fischer K, Cramer P, Busch R, et al.: Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29 (26): 3559-66, 2011.</Citation><Citation idx="38" PMID="21371003">Iannitto E, Morabito F, Mancuso S, et al.: Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. Br J Haematol 153 (3): 351-7, 2011.</Citation><Citation idx="39" PMID="19652068">Knauf WU, Lissichkov T, Aldaoud A, et al.: Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27 (26): 4378-84, 2009.</Citation><Citation idx="40" PMID="21189385">Chen CI, Bergsagel PL, Paul H, et al.: Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 29 (9): 1175-81, 2011.</Citation><Citation idx="41" PMID="17088571">Chanan-Khan A, Miller KC, Musial L, et al.: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24 (34): 5343-9, 2006.</Citation><Citation idx="42" PMID="18334676">Ferrajoli A, Lee BN, Schlette EJ, et al.: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111 (11): 5291-7, 2008.</Citation><Citation idx="43" PMID="21725050">Badoux XC, Keating MJ, Wen S, et al.: Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 118 (13): 3489-98, 2011.</Citation><Citation idx="44" PMID="21879809">Wendtner CM, Hillmen P, Mahadevan D, et al.: Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma 53 (3): 417-23, 2012.</Citation><Citation idx="45" PMID="23270003">Badoux XC, Keating MJ, Wen S, et al.: Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 31 (5): 584-91, 2013.</Citation><Citation idx="46" PMID="17971612">Moutouh-de Parseval LA, Weiss L, DeLap RJ, et al.: Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 25 (31): 5047, 2007.</Citation><Citation idx="47" PMID="21803850">Smith MR, Neuberg D, Flinn IW, et al.: Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood 118 (13): 3525-7, 2011.</Citation><Citation idx="48" PMID="20962860">Carney DA, Westerman DA, Tam CS, et al.: Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 24 (12): 2056-62, 2010.</Citation><Citation idx="49" PMID="19075280">Lamanna N, Jurcic JG, Noy A, et al.: Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 27 (4): 491-7, 2009.</Citation><Citation idx="50" PMID="19075274">Foon KA, Boyiadzis M, Land SR, et al.: Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27 (4): 498-503, 2009.</Citation><Citation idx="51" PMID="18411418">Tam CS, O'Brien S, Wierda W, et al.: Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112 (4): 975-80, 2008.</Citation><Citation idx="52" PMID="21245487">Badoux XC, Keating MJ, Wang X, et al.: Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117 (11): 3016-24, 2011.</Citation><Citation idx="53" PMID="21321292">Woyach JA, Ruppert AS, Heerema NA, et al.: Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol 29 (10): 1349-55, 2011.</Citation><Citation idx="54" PMID="20194844">Robak T, Dmoszynska A, Solal-Céligny P, et al.: Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28 (10): 1756-65, 2010.</Citation><Citation idx="55" PMID="17008537">Kay NE, Geyer SM, Call TG, et al.: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109 (2): 405-11, 2007.</Citation><Citation idx="56" PMID="17514743">Shanafelt TD, Lin T, Geyer SM, et al.: Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 109 (11): 2291-8, 2007.</Citation><Citation idx="57" PMID="21498674">Wierda WG, Kipps TJ, Dürig J, et al.: Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 117 (24): 6450-8, 2011.</Citation><Citation idx="58" PMID="2016618" MedlineID="91202201">Raphael B, Andersen JW, Silber R, et al.: Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol 9 (5): 770-6, 1991.</Citation><Citation idx="59" PMID="8069190" MedlineID="94348383">Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. French Cooperative Group on Chronic Lymphocytic Leukemia. Leuk Lymphoma 13 (5-6): 449-56, 1994.</Citation><Citation idx="60" PMID="17283364">Flinn IW, Neuberg DS, Grever MR, et al.: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25 (7): 793-8, 2007.</Citation><Citation idx="61" PMID="17658394">Catovsky D, Richards S, Matutes E, et al.: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370 (9583): 230-9, 2007.</Citation><Citation idx="62" PMID="12228208" MedlineID="22215760">Morrison VA, Rai KR, Peterson BL, et al.: Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 20 (18): 3878-84, 2002.</Citation><Citation idx="63" PMID="15738539">Moreton P, Kennedy B, Lucas G, et al.: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23 (13): 2971-9, 2005.</Citation><Citation idx="64" PMID="21750315">Parikh SA, Keating MJ, O'Brien S, et al.: Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 118 (8): 2062-8, 2011.</Citation><Citation idx="65" PMID="22493413">Pettitt AR, Jackson R, Carruthers S, et al.: Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol 30 (14): 1647-55, 2012.</Citation><Citation idx="66" PMID="19597025">Stilgenbauer S, Zenz T, Winkler D, et al.: Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 27 (24): 3994-4001, 2009.</Citation><Citation idx="67" PMID="19641526">Cortelezzi A, Pasquini MC, Gardellini A, et al.: Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 23 (11): 2027-33, 2009.</Citation><Citation idx="68" PMID="19626051">Osterborg A, Foà R, Bezares RF, et al.: Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 23 (11): 1980-8, 2009.</Citation><Citation idx="69" PMID="21919823">Gritti G, Reda G, Maura F, et al.: Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Leuk Lymphoma 53 (3): 424-9, 2012.</Citation><Citation idx="70" PMID="20697069">Lin TS, Donohue KA, Byrd JC, et al.: Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 28 (29): 4500-6, 2010.</Citation><Citation idx="71" PMID="21670470">Badoux XC, Keating MJ, Wang X, et al.: Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood 118 (8): 2085-93, 2011.</Citation><Citation idx="72" PMID="22337714">Lepretre S, Aurran T, Mahé B, et al.: Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood 119 (22): 5104-10, 2012.</Citation><Citation idx="73" PMID="21992852">Elter T, Gercheva-Kyuchukova L, Pylylpenko H, et al.: Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol 12 (13): 1204-13, 2011.</Citation><Citation idx="74" PMID="18682948">Elter T, Vehreschild JJ, Gribben J, et al.: Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol 88 (2): 121-32, 2009.</Citation><Citation idx="75" PMID="19863336">Byrd JC, Peterson BL, Rai KR, et al.: Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma 50 (10): 1589-96, 2009.</Citation><Citation idx="76" PMID="12058231" MedlineID="22052470">Doney KC, Chauncey T, Appelbaum FR, et al.: Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant 29 (10): 817-23, 2002.</Citation><Citation idx="77" PMID="12860954">Schetelig J, Thiede C, Bornhauser M, et al.: Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 21 (14): 2747-53, 2003.</Citation><Citation idx="78" PMID="15205268">Ritgen M, Stilgenbauer S, von Neuhoff N, et al.: Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 104 (8): 2600-2, 2004.</Citation><Citation idx="79" PMID="15809449">Moreno C, Villamor N, Colomer D, et al.: Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 23 (15): 3433-8, 2005.</Citation><Citation idx="80" PMID="12194718">Khouri IF, Keating MJ, Saliba RM, et al.: Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 4 (3): 217-21, 2002.</Citation><Citation idx="81" PMID="16043827">Pavletic SZ, Khouri IF, Haagenson M, et al.: Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol 23 (24): 5788-94, 2005.</Citation><Citation idx="82" PMID="22490331">Dreger P, Döhner H, McClanahan F, et al.: Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. Blood 119 (21): 4851-9, 2012.</Citation><Citation idx="83" PMID="21406717">Sutton L, Chevret S, Tournilhac O, et al.: Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood 117 (23): 6109-19, 2011.</Citation><Citation idx="84" PMID="15809448">Sorror ML, Maris MB, Sandmaier BM, et al.: Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 23 (16): 3819-29, 2005.</Citation><Citation idx="85" PMID="22640008">Toze CL, Dalal CB, Nevill TJ, et al.: Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. Br J Haematol 158 (2): 174-85, 2012.</Citation><Citation idx="86" PMID="15117764">Milligan DW, Fernandes S, Dasgupta R, et al.: Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 105 (1): 397-404, 2005.</Citation><Citation idx="87" PMID="17456058">Khouri IF, Saliba RM, Admirand J, et al.: Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 137 (4): 355-63, 2007.</Citation><Citation idx="88" PMID="18794548">Sorror ML, Storer BE, Sandmaier BM, et al.: Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 26 (30): 4912-20, 2008.</Citation><Citation idx="89" PMID="18711173">Schetelig J, van Biezen A, Brand R, et al.: Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 26 (31): 5094-100, 2008.</Citation><Citation idx="90" PMID="18798106">Malhotra P, Hogan WJ, Litzow MR, et al.: Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. Leuk Lymphoma 49 (9): 1724-30, 2008.</Citation><Citation idx="91" PMID="20595516">Dreger P, Döhner H, Ritgen M, et al.: Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 116 (14): 2438-47, 2010.</Citation><Citation idx="92" PMID="23435461">Dreger P, Schnaiter A, Zenz T, et al.: TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood 121 (16): 3284-8, 2013.</Citation><Citation idx="93" PMID="21830940">Porter DL, Levine BL, Kalos M, et al.: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365 (8): 725-33, 2011.</Citation><Citation idx="94" PMID="24578504">Maus MV, Grupp SA, Porter DL, et al.: Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123 (17): 2625-35, 2014.</Citation></ReferenceSection></SummarySection><SummarySection id="_101"><SectMetaData><SpecificDiagnosis ref="CDR0000038728">refractory chronic lymphocytic leukemia</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Recurrent or Refractory CLL</Title><Para id="_102">Clinical trials are appropriate and should be considered when possible.<Reference refidx="1"/> 
 In small studies, response rates of more than 40% have been reported for lenalidomide <Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/> and flavopiridol.<Reference refidx="5"/><Reference refidx="6"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]   The addition of the Bcl-2 anti-sense oligonucleotide oblimersen to fludarabine/cyclophosphamide improved complete response rates in a randomized study of 241 patients with relapsed disease.<Reference refidx="7"/>[<LOERef href="CDR0000587983">Level of evidence: 1iiDiv</LOERef>] Bone marrow and peripheral stem
cell transplantations are under clinical evaluation.<Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/>
</Para><SummarySection id="_TrialSearch_101_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_101_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38728&amp;tt=1&amp;format=2&amp;cn=1">refractory chronic lymphocytic leukemia</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_101_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="9482528" MedlineID="98141632">Byrd JC, Rai KR, Sausville EA, et al.: Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals. Semin Oncol 25 (1): 65-74, 1998.</Citation><Citation idx="2" PMID="17088571">Chanan-Khan A, Miller KC, Musial L, et al.: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24 (34): 5343-9, 2006.</Citation><Citation idx="3" PMID="18334676">Ferrajoli A, Lee BN, Schlette EJ, et al.: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111 (11): 5291-7, 2008.</Citation><Citation idx="4" PMID="18427150">Andritsos LA, Johnson AJ, Lozanski G, et al.: Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 26 (15): 2519-25, 2008.</Citation><Citation idx="5" PMID="17003373">Byrd JC, Lin TS, Dalton JT, et al.: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109 (2): 399-404, 2007.</Citation><Citation idx="6" PMID="19826119">Lin TS, Ruppert AS, Johnson AJ, et al.: Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 27 (35): 6012-8, 2009.</Citation><Citation idx="7" PMID="19738118">O'Brien S, Moore JO, Boyd TE, et al.: 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 27 (31): 5208-12, 2009.</Citation><Citation idx="8" PMID="15830011">Dreger P, Brand R, Milligan D, et al.: Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 19 (6): 1029-33, 2005.</Citation><Citation idx="9" PMID="12860954">Schetelig J, Thiede C, Bornhauser M, et al.: Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 21 (14): 2747-53, 2003.</Citation><Citation idx="10" PMID="15205268">Ritgen M, Stilgenbauer S, von Neuhoff N, et al.: Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 104 (8): 2600-2, 2004.</Citation><Citation idx="11" PMID="15809449">Moreno C, Villamor N, Colomer D, et al.: Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 23 (15): 3433-8, 2005.</Citation><Citation idx="12" PMID="12194718">Khouri IF, Keating MJ, Saliba RM, et al.: Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 4 (3): 217-21, 2002.</Citation><Citation idx="13" PMID="12058231" MedlineID="22052470">Doney KC, Chauncey T, Appelbaum FR, et al.: Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. Bone Marrow Transplant 29 (10): 817-23, 2002.</Citation><Citation idx="14" PMID="16043827">Pavletic SZ, Khouri IF, Haagenson M, et al.: Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol 23 (24): 5788-94, 2005.</Citation></ReferenceSection></SummarySection><SummarySection id="_129"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (04/02/2015)</Title><Para id="_130">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available.  This section describes the latest changes made to this summary as of the date above.</Para><Para id="_365">Editorial changes were made to this summary.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062856#_AboutThis_1" url="http://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of chronic lymphocytic leukemia. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Chronic Lymphocytic Leukemia Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Eric J. Seifter, MD (Johns Hopkins University)</ListItem><ListItem>Mikkael A. Sekeres, MD, MS (Cleveland Clinic Taussig Cancer Institute)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® Chronic Lymphocytic Leukemia Treatment. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq">http://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection> 

  <SummarySection id="_GetMore_3"><Title>Get More Information From NCI</Title><Para id="_GetMore_15"><Emphasis><Strong>Call 1-800-4-CANCER</Strong></Emphasis></Para><Para id="_GetMore_16">For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time.  A trained Cancer Information Specialist is available to answer your questions.</Para><Para id="_GetMore_25"><Emphasis><Strong>Chat online 
</Strong></Emphasis></Para><Para id="_GetMore_26">The <ExternalRef xref="https://livehelp.cancer.gov/">NCI's LiveHelp®</ExternalRef> online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
</Para><Para id="_GetMore_27"><Emphasis><Strong>Write to us</Strong></Emphasis></Para><Para id="_GetMore_28">For more information from the NCI, please write to this address:</Para><ItemizedList id="_GetMore_29" Style="simple"><ListItem>NCI Public Inquiries Office</ListItem><ListItem>9609 Medical Center Dr. </ListItem><ListItem>Room 2E532 MSC 9760</ListItem><ListItem>Bethesda, MD 20892-9760</ListItem></ItemizedList><Para id="_GetMore_17"><Emphasis><Strong>Search the NCI Web site</Strong></Emphasis></Para><Para id="_GetMore_18">The <ExternalRef xref="http://cancer.gov">NCI Web site</ExternalRef> provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families.  For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.</Para><Para id="_GetMore_30">There are also many other places to get materials and information about cancer treatment and services.      Hospitals in your area may have information about  local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.</Para><Para id="_GetMore_19"><Emphasis><Strong>Find Publications</Strong></Emphasis></Para><Para id="_GetMore_20">The NCI has booklets and other materials for patients, health professionals, and the public.  These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials.  Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities.  NCI materials on these and other topics may be ordered online or printed directly from the <ExternalRef xref="https://pubs.cancer.gov/ncipl">NCI Publications Locator</ExternalRef>. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</Para></SummarySection><DateLastModified>2015-04-02</DateLastModified></Summary>
